328 related articles for article (PubMed ID: 17368821)
1. Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia.
Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Biomed Pharmacother; 2007 Jul; 61(6):306-14. PubMed ID: 17368821
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccines in acute leukaemia.
Duncan C; Roddie H
Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
[TBL] [Abstract][Full Text] [Related]
4. Principles of dendritic cell-based immunotherapy in myeloid leukemia.
Westers TM; Houtenbos I; van de Loosdrecht AA; Ossenkoppele GJ
Immunobiology; 2006; 211(6-8):663-76. PubMed ID: 16920505
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia.
Roddie H; Klammer M; Thomas C; Thomson R; Atkinson A; Sproul A; Waterfall M; Samuel K; Yin J; Johnson P; Turner M
Br J Haematol; 2006 Apr; 133(2):152-7. PubMed ID: 16611305
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Immunobiology; 2006; 211(6-8):677-85. PubMed ID: 16920506
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches].
Mohty M; Gaugler B; Calmels B; Blaise D; Vey N; Chabannon C; Olive D
Bull Cancer; 2003; 90(8-9):751-7. PubMed ID: 14609765
[TBL] [Abstract][Full Text] [Related]
8. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
Klammer M; Roddie PH
Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccines for leukemia patients.
Schmitt A; Hus I; Schmitt M
Expert Rev Anticancer Ther; 2007 Mar; 7(3):275-83. PubMed ID: 17338648
[TBL] [Abstract][Full Text] [Related]
10. Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2006 Aug; 134(4):445-6; author reply 446-7. PubMed ID: 16822293
[No Abstract] [Full Text] [Related]
11. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation.
Rasaiyaah J; Yong K; Katz DR; Kellam P; Chain BM
Br J Haematol; 2007 Aug; 138(3):281-90. PubMed ID: 17614817
[TBL] [Abstract][Full Text] [Related]
13. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.
Kitawaki T; Kadowaki N; Fukunaga K; Kasai Y; Maekawa T; Ohmori K; Itoh T; Shimizu A; Kuzushima K; Kondo T; Ishikawa T; Uchiyama T
Exp Hematol; 2011 Apr; 39(4):424-433.e2. PubMed ID: 21216276
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with dendritic cells for cancer.
Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
[TBL] [Abstract][Full Text] [Related]
15. In-vivo generation of leukaemia-derived dendritic cells.
Kolb HJ; Rank A; Chen X; Woiciechowsky A; Roskrow M; Schmid C; Tischer J; Ledderose G
Best Pract Res Clin Haematol; 2004 Sep; 17(3):439-51. PubMed ID: 15498715
[TBL] [Abstract][Full Text] [Related]
16. [Dendritic cell-based therapeutic vaccination for acute myeloid leukemia].
Anguille S; Van Tendeloo V; Berneman Z
Bull Cancer; 2012 Jun; 99(6):635-42. PubMed ID: 22641288
[TBL] [Abstract][Full Text] [Related]
17. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Haematologica; 2006 Mar; 91(3):348-55. PubMed ID: 16531258
[TBL] [Abstract][Full Text] [Related]
18. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
20. Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia.
Dietz AB; Litzow MR; Gastineau DA; Vuk-Pavlović S
Croat Med J; 2001 Aug; 42(4):428-35. PubMed ID: 11471194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
